Print
Skip left navigation

Medicare Advantage Prior Authorization for Chemotherapy and Related Cancer Therapies

Beginning Oct. 1, 2019, we’ll require prior authorization for outpatient injectable chemotherapy and related cancer therapies for most UnitedHealthcare Medicare health plan members, including AARP® MedicareComplete®, Care Improvement Plus®, UnitedHealthcare Dual Complete® and UnitedHealthcare® Group Medicare Advantage plans. Optum, an affiliate company of UnitedHealthcare, will help manage these prior authorization requests. Members in institutional Special Needs Plans, Erickson Advantage® plans and UnitedHealthcare West plans (noted by ‘WEST’ on the back of the member ID card) are delayed from requiring prior authorization.

UnitedHealthcare Medicare Advantage health plan members in Florida, Georgia and Wisconsin, who previously required notification for outpatient injectable chemotherapy through the vendor eviCore, are now required to obtain prior authorization through Optum. Previously approved notifications will remain active until the approved end date, or until there’s a change in treatment. At that time, Optum will require a new prior authorization request.

If a member receives injectable chemotherapy drugs or related cancer therapies in an outpatient setting between July 1, 2019 and Sept. 30, 2019, you don’t need to request prior authorization until you administer a new chemotherapy drug or related cancer therapy. We’ll authorize the chemotherapy regimen the member was receiving prior to Oct. 1, 2019. The authorization will be effective until Sept. 30, 2020.

Program Requirements

Injectable chemotherapy drugs that require prior authorization:

  • Injectable chemotherapy drugs (J9000 - J9999)
  • Leucovorin (J0640)
  • Levoleukovorin (J0641)
  • Injectable chemotherapy drugs that have a Q code
  • Injectable chemotherapy drugs that have not yet received an assigned code and will be billed under a miscellaneous Healthcare Common Procedure Coding System (HCPCS) code will require prior authorization

Colony-stimulating factors when requested for use to treat a cancer diagnosis requires prior authorization:

  • J1442 Filgrastim (Neupogen®)
  • J1447 Tbo-filgrastim (Granix®)
  • J2505 Pegfilgrastim (Neulasta®)
  • J2820 Sargramostim (Leukine®)
  • Q5101 Filgrastim, bio similar (Zarxio®)
  • Q5108 Pegfilgrastim-jmdb (Fulphila™)
  • Q5110 Filgrastim-aafi (Nivestym™)
  • Q5111 Pegfilgrastim-cbqv, biosimilar, (Udenyca™)
  • Colony-stimulating factors that have not yet received an assigned code and will be billed under a temporary or miscellaneous HCPCS code

Bone modifying agent when requested for a cancer diagnosis requires prior authorization:

  • J0897 Denosumab

Prior authorization is NOT required for the following*:

  • Oral chemotherapy drugs, which are covered under a member’s pharmacy benefit plan
  • Use of chemotherapy drugs for non-cancer diagnosis 

Note: Adding a new injectable chemotherapy drug, colony-stimulating factor or denosumab to a regimen will require a new prior authorization request.

How We Make Decisions About Prior Authorization

Prior authorization is a process we use to help improve care experiences, outcomes and the cost of care for our plan members. We cover chemotherapy, associated drugs and treatments when Medicare coverage criteria are met. We cover chemotherapy, immunotherapy and hormonal agents when medically indicated and used according to Food and Drug Administration (FDA)-approved indications, or as part of an anticancer chemotherapeutic regimen or cancer treatment regimen.

UnitedHealthcare follows Medicare coverage guidelines, such as national coverage determinations (NCDs), local coverage determinations (LCDs) and other Original Medicare manuals. In the absence of a Medicare LCD, NCD or other Medicare coverage guidance, the Centers for Medicare & Medicaid Services (CMS) allows a Medicare Advantage Organization (MAO) to create its own coverage determinations. MAO’s are able to use objective evidence-based rationale that focuses on industry-leading evidence from specialty society research and studies.

 In the absence of a Medicare NCD or LCD, we use National Comprehensive Cancer Network® (NCCN®) guidelines to review prior authorization requests and claims for coverage of chemotherapy drugs administered in an outpatient setting. NCCN provides independent, evidence-based recommendations for cancer treatment and is a CMS recognized compendium. You can view their guidelines at nccn.org > NCCN Guidelines®.

How to Request Prior Authorization

To submit an online request for prior authorization, use the Prior Authorization and Notification tool on Link to submit your request. To access the tool, sign in to Link by going to UHCprovider.com and clicking on the Link button in the top right corner. Once you’re in the tool, select Oncology, and when prompted, answer the questions about the service type, member type and state.

Please complete all prior authorization requests online. The online system will identify the members who need a prior authorization request submitted.

If you have questions about prior authorizations for UnitedHealthcare members, please call 888-397-8129, 8 a.m. to 5 p.m., local time, Monday through Friday. 

Additional Resources

Need Help?

If you have program questions and need more information, please email unitedoncology@uhc.com.


*Member coverage documents and health plans may require prior authorization for some non-chemotherapy services. Care providers should contact the Customer Service phone number on the back of the member’s ID card for more information. If you have questions about oral chemotherapy drugs, please contact the member’s Pharmacy Benefit Plan by calling the number on the back of the member’s ID card.

Note: For members in plans managed by MDX Health®, Lifeprint, OptumCare® and Wellmed ® please follow the delegate’s process for notification. This requirement excludes UnitedHealthcare West membership.

NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN® and NCCN GUIDELINES® are trademarks ("Marks") of the National Comprehensive Cancer Network, Inc.